Latest sickle cell anemia Stories
Data Demonstrate Hydroxyurea Therapy Offers Safe, Effective Disease Management CINCINNATI, Nov.
MST-188 Significantly Decreased Thrombin Generation in Blood of Sickle Cell Anemia Patients SAN DIEGO, Nov.
Computer Systems Institute (CSI) in Gurnee will host a Marrow Donor Registry Drive to find potential donor matches for seven-year old Nyiah and others who live with diseases such as leukemia and
Malikah Amoh puts families first, founds "Timmy's Heart," a foundation for Sickle Cell awareness.
A team of researchers led by scientists at Weill Cornell Medical College has designed what appears to be a powerful gene therapy strategy that can treat both beta-thalassemia disease and sickle cell anemia.
The disparity in stroke-related deaths among black and white children dramatically narrowed after prevention strategies changed to include ultrasound screening and chronic blood transfusions for children with sickle cell anemia.
Young infants and toddlers with sickle cell anemia who received the drug hydroxyurea were no more likely to have cellular genetic damage than those who received a placebo or inactive medicine.
Research assessing the safety and efficacy of hydroxyurea therapy in pediatric patients with sickle cell disease (SCD) and the use of pre-operative transfusions for patients with SCD who undergo low- and moderate-risk elective surgery will be presented today at the 53rd Annual Meeting of the American Society of Hematology.